Deutsche Märkte schließen in 7 Stunden 13 Minuten

Rogers Corporation (ROG)

NYSE - Nasdaq Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
259,33+2,60 (+1,01%)
Börsenschluss: 04:00PM EDT
259,33 0,00 (0,00%)
Nachbörse: 04:02PM EDT
Melden Sie sich an, um eine Nachricht zu posten.
  • f
    friendlyadvice
    $BIIB conversation
    BIIB $TAK $ROG $HTBX $FB helping with the Coronavirus fight, just some... Coronavirus stocks have been an excellent hedge against the Coronavirus... The Coronavirus eventually will go away, so what is up next after CV? Stocks that work on Antibiotic resistant drugs is perhaps the next HOTTEST sector to look into! Here is one to research, any other ANTIBIOTIC companies to research? Let me know please! All large cap Tech & Biotech companies ought to spend their HUGE cash positions and start working antibiotic resistant medications, the next area: "In little more than 30 years, antibiotic-resistance may be more deadly than cancer around the globe. At least 23,000 people in the US die of an antibiotic-resistant infection each year - and some estimates suggest it's far more."

    Antibiotic resistance: the hidden threat lurking behind Covid-19
    "As we come together to fight today’s Covid-19 crisis, we must also look ahead to the next one. We cannot be short-sighted, and we cannot be complacent, especially about antibiotic resistance. We must put measures in place to ensure that we have the antibiotics we need — today and in the future. The time to act is now."
    March 23, 2020:
    https://www.statnews.com/2020/03/23/antibiotic-resistance-hidden-threat-lurking-behind-covid-19/

    One to look at is the new ACRX, which merged w/ TTPH, TTPH shareholders received ACRX shares about 16% of the ACRX shares (agreed to mid March, which combines both ACRX & TTPH FDA & EU approved drugs, and sales teams.... TTPH has a recent FDA & EU antibiotic drug that recently launched in the United States: March 16, 2020: "AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals"

    TTPH CEO: "I'd like to acknowledge the recent increased public recognition around the growing threat of antibiotic resistance and the urgent need for new therapies to address multidrug-resistant infections. Despite this growing threat and awareness the number of new treatments in development remains alarmingly small relative to other therapeutic areas. The challenges facing drug developers in this field are clear, and appropriate incentives to remove barriers to development and stimulate innovation in the antibiotic space are needed to improve the treatment paradigm to ensure patients receive the best care for these life-threatening infections."

    TTPH’s FDA & EU approved XERAVA (FDA approved about 3 months earlier than DSUVIA, XERAVA Q4 Revenue up 45% over Q3 Revenue): TTPH's recent launched XERAVA: https://xerava.com/ Think XERAVA could be huge in the fight against ANTIBIOTIC resistant drugs!

    NOTE an older article on ACRX, and note in April 2020 (thereabout now) the Department of Defense starts buying ACRX's FDA approved drug...

    AcelRx Announces Confirmed Timing of Department of Defense Milestone C Meeting for April
    March 10, 2020

    """DSUVIA to fulfill an unmet need for our injured soldiers""""

    "We are excited to have a confirmed date for the Milestone C meeting and expect DSUVIA® will soon be made available more broadly for military use," said Vince Angotti, Chief Executive Officer of AcelRx Pharmaceuticals. "The Department of Defense has been a great partner supporting the development of DSUVIA since 2011, and this is the final stage in the process that enables us to provide DSUVIA to fulfill an unmet need for our injured soldiers," continued Angotti.

    3 Stocks to Hold for the Next 20 Year
    "AcelRx thinks this drug can eventually generate more than $1 billion in annual sales."
    "So while AcelRx's stock might not take off right away, it should turn out to be a stellar long-term biotech play."
    https://www.fool.com/investing/2018/12/01/3-stocks-to-hold-for-the-next-20-years.aspx

    RESEARCHING for the next winner... Any thoughts, much appreciated...
    Antibiotic resistance will be a problem with Covid-19. When it weakens the body, it's easier for hard-to-treat bacteria to take hold.
    Antibiotic resistance will be a problem with Covid-19. When it weakens the body, it's easier for hard-to-treat bacteria to take hold.
    www.statnews.com
  • F
    Fnssie
    $ROG conversation
    $ROG Bullish technical indication in MACD, Stochastic oscillator and RSI at stoxline.
  • L
    Lauren
    $ROG conversation
    Found some interesting information regarding shorts for $ROG https://marketwirenews.com/short-information/NYSE/ROG
  • J
    JOHNNY CASH
    88 Energy Limited
    GET IN $ROG on asx right now
    it's about to POP

    better then 88EE

    undervalued
  • R
    RogerDurk
    $ROG conversation
    wow, taking quite a hit, guess the street didn't like the guidance https://finance.yahoo.com/news/rogers-corp-posts-2q-profit-203128624.html
    Rogers Corp. posts 2Q profit
    On a per-share basis, the Rogers, Connecticut-based company said it had profit of 29 cents. Earnings, adjusted for non-recurring costs, were 88 cents per share. The specialty materials company posted revenue ...
    finance.yahoo.com